Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase StudyCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Use of PCSO-524® in Combination with Prednisolone for Treatment of Spinal Cord Injury from Disc Protrusion in Dogs
Male Shih tzu dog aged 9 years and 1 month was diagnosed with limb paralysis after jumping 4 days prior to the hospital visit.
The dog showed weak response of forelimb reflex and severe neck pain. X-ray examination showed block vertebrae at C3 and C4.
Magnetic resonance imaging (MRI) examination found mild disc protrusion, compression on spinal cord and myelopathy at C4 and C5 with compression on the right dorsal lamina.
Prednisolone and gabapentin were prescribed to reduce inflammation and pain, respectively.
Follow-up after reduction of prednisolone showed that the dog fell more often while walking and slight neck pain was present. Prednisolone dosage was then increased and PCSO-524® was prescribed to reduce inflammation of the spinal cord. Later examination found that the dog could walk without falling, both forelimbs showed normal reflex, and signs of neck pain disappeared. Termination of prednisolone was then started without any recurrent clinical signs.
After continuous treatment with PCSO-524® for 6 weeks, the dog could walk normally, both forelimbs showed normal reflex, and the ALK level was nearly back to the level prior to the treatment.
Effectiveness of Disease Modifying Osteoarthritis Agents and Carprofen for Treatment of Canine Osteoarthritis
A prospective, randomized, single-blinded study was conducted to evaluate and compare the effectiveness of disease modifying osteoarthritis agents (DMOAAs) and carprofen by using force plate gait analysis and orthopaedic assessment score (OAS) in osteoarthritic dogs.
Forty dogs with hip and/or stifle osteoarthritis (OA) were assigned randomly into four treatment groups:
PCSO-524, treated with a marine-based fatty-acid compound; GC-ASU, treated with a combination of glucosamine-chondroitin sulphate and avocado/soybean unsaponifiables; CPF, treated with carprofen; and CPF-PCSO, treated with a combination of carprofen and PCSO-524. Each group received the therapeutic agent orally for four weeks.
Peak vertical force (PVF), OAS, haematology and blood chemistry values were evaluated before treatment, and on the second and fourth weeks post-treatment.
No significant effect was found in the PVF, OAS and blood values among the four treatment groups.
Effect of PCSO-524 on OA Biomarkers and Weight Bearing Properties in Canine Shoulder and Coxofemeral Osteoarthritis
This trial included 66 mixed breed dogs with x-ray confirmed OA split into two treatment groups for 24 weeks. These were 1) PCSO-524 (5 mg/kg) and 2) fish oil (2,000 mg/d). The dogs were all placed on a standardised diet to minimise variability.
The results suggest that PCSO-524 is protective against cartilage breakdown in dogs with osteoarthritis.
The Effectiveness of Marine Based Fatty Acid Compound and NSAIDs for the Treatment of Canine Osteoarthritis: a preliminary study
The Objectives of this study were to investigate the effectiveness of PCSO-524, NSAIDs and combination of NSAIDs and PCSO-524 in the treatment of canine osteoarthritis through the use of force plate gait analysis.
Study Design: A prospective block-randomized single-blinded study.
Animals: Thirty client-owned dogs that had clinical and radiographic evidences of hip or stifle osteoarthritis.
Application of the Polyunsaturated fatty acid compound PCSO-524 in the post operative recovery of dogs that have had stifle surgery
World Small Animal Veterinary Assoc.
38th Annual Congress 6-9 March 2013, Auckland, New Zealand
The clinical outcomes of the use of PCSO-524 in 28 dogs that had undergone surgery on the stifle (which included correction of the patellar luxation and correction of cranial cruciate ligament rupture) were studied at the Small Animal Teaching Hospital, at Chulalongkorn University, Bangkok, Thailand.
Twenty-eight dogs that undergone both stifle surgery were included in our study. All test subjects had been given pre-emptive analgesia (morphine sulfate). NSAIDs and glucosamine had been administered before the surgery.
Two postoperative treatments were:
- NSAIDs treatment for one week in combination with glucosamine sulfate;
- only PCSO-524 treatments.
The Preliminary study of the Clinical outcome of using the PCSO-524 polyunsaturated fatty acid compound (Antinol) in the treatment of Canine Osteoarthritis and degenerative spinal diseases
Authors:
The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University.
Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome.
All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks.
Use of Acupuncture in Combination with PCSO-524® (Antinol®) for Treatment of Hindlimb Paresis in Prairie Dogs
Authors:
A prairie dog was admitted to the hospital due to falling from a height accident.
During 2 weeks of admission, the animal was treated with steroid and vitamin B, however, no response was observed.
Alternative medicine; acupuncture, was then applied in combination with PCSO-524® (Antinol®) to enhance the effects of acupuncture on pain relief and repairing the damaged neurons.
Excellent recovery was observed after 1 month of the treatment.
The animal could stand in normal position, express other normal gestures, and the reflex was nearly fully recovered.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
